Synthetic calcium phosphate comprising silicon and trivalent cation 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2007003634 A1 2007-01-04 [US20070003634]US7695740 B2 2010-04-13 [US7695740] / 2007-01-042010-04-13
申请号/申请日
2005US-11168420 / 2005-06-29
发明人
GIBSON IAIN RONALD;SKAKLE JANET MABEL SCOTT;STEPHEN JENNIFER ANNE;BUCKLAND THOMAS;
申请人
BUCKLAND THOMAS;GIBSON IAIN RONALD;SKAKLE JANET MABEL SCOTT;STEPHEN JENNIFER ANNE;
主分类号
IPC分类号
A01N-055/00A01N-059/26A61F-002/00A61K-031/28A61K-033/42
摘要
(US7695740) Biomedical materials and, in particular, to substituted calcium phosphate (e.g. apatite and hydroxyapatite) materials for use as synthetic bone.  A synthetic calcium phosphate comprising silicon and a trivalent cation having a formula Ca10&minus;yMy(PO4)6&minus;x(SiO4)x(OH)2&minus;x+y where M is a trivalent cation, 0<x<1.3 and 0<y<1.3.  The trivalent cation is one or more of yttrium, scandium, aluminium and the Lanthanide elements.  Preferably, the trivalent cation is or comprises yttrium.  The trivalent cation is believed to substitute for the calcium ion in the hydroxyapatite lattice.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2005US-11168420 2005-06-29
主权利要求
(US7695740) The invention claimed is: 1.  A synthetic calcium phosphate-based biomedical material comprising silicon and a trivalent cation wherein the material comprises a compound having the chemical formula:    Ca10-yMy(PO4)6-x(SiO4)x(OH)2-x+y     where M is a trivalent cation, 0<x<1.3 and 0<y<1.3 and wherein the trivalent cation is selected from one or more of yttrium, scandium, aluminum and the Lanthanide elements. 2. The biomedical material according to claim 1, wherein the calcium phosphate-based biomedical material comprises hydroxyapatite or apatite. 3. The biomedical material according to claim 1, wherein 0<x<1.1. 4. The biomedical material according to claim 3, wherein 0.5<x<1.1. 5. The biomedical material according to claim 1, wherein 0<y<1.1. 6. The biomedical material according to claim 5, wherein 0.5<y<1.1. 7. The biomedical material according to claim 1, wherein x >= y. 8. The biomedical material according to claim 1, wherein y >= x. 9. The biomedical material according to claim 1, wherein the phase purity of the biomedical material, as measured by X-ray diffraction, is at least 95%. 10. The biomedical material according to claim 1, wherein the biomedical material comprises one or more secondary phases. 11. The biomedical material according to claim 10, wherein the secondary phases comprise one or more of tricalcium phosphate, alpha or beta polymorphs thereof, calcium silicate, tetracalcium phosphate, calcium carbonate, calcium oxide, monetite, brushite, calcium pyrophosphate and octacalcium phosphate. 12. The biomedical material according to claim 1, wherein the trivalent cation is yttrium. 13. A synthetic bone material, bone implant, bone graft, bone substitute, bone scaffold, filler, coating or cement comprising a biomedical material as defined in claim 1. 14. A process for the synthesis of a calcium phosphate-based material of claim 1 comprising silicon and a trivalent cation, the process comprising: providing calcium or a calcium-containing compound, a trivalent cation-containing compound, a phosphorus-containing compound and a silicon-containing compound; and   forming a precipitate by reacting the compounds in an aqueous phase at an alkali pH. 15. The process according to claim 14, wherein the calcium phosphate-based material comprises hydroxyapatite or apatite. 16. The process according to claim 14, wherein the calcium-containing compound comprises a calcium salt. 17. The process according to claim 16, wherein the calcium salt is selected from one or more of calcium hydroxide, calcium chloride, calcium nitrate and/or calcium nitrate hydrate. 18. The process according to claim 14, wherein the trivalent cation-containing compound comprises a compound of yttrium. 19. The process according to claim 18, wherein the yttrium compound is selected from one or both of yttrium chloride and/or yttrium nitrate. 20. The process according to claim 18, wherein yttrium is present in the material in an amount of up to 13 weight percent. 21. The process according to claim 18, wherein yttrium is present in the material in an amount of up to 20 weight percent. 22. The process according to claim 14, wherein the phosphorus-containing compound is selected from one or both of a phosphate salt and/or a phosphoric acid. 23. The process according to claim 22, wherein the phosphorus-containing compound is selected from one or both of ammonium phosphate and/or phosphoric acid. 24. The process according to claim 14, wherein the silicon-containing compound comprises a silicate. 25. The process according to claim 24, wherein the silicate is selected from one or both of tetraethyl orthosilicate (TEOS) and/or silicon acetate. 26. The process according to claim 24, wherein the silicate is present in the material in an amount of up to 13 weight percent. 27. The process according to claim 24, wherein the silicate is present in the material in an amount of up to 20 weight percent. 28. The process according to claim 14, wherein the pH is from 8 to 13. 29. The process according to claim 28, wherein the pH is from 10 to 12. 30. The process according to claim 14, wherein an alkali is added to adjust the pH of the solution to the desired pH. 31. The process according to claim 30, wherein the alkali is ammonium hydroxide or concentrated ammonia. 32. The process according to claim 14, wherein after the precipitate has been formed it is dried, heated and/or sintered. 33. The process according to claim 32, wherein the precipitate is heated and/or sintered to a temperature in the range of from 800 deg. C. to 1500 deg. C. 34. The process according to claim 33, wherein the precipitate is heated and/or sintered to a temperature in the range of from 1000 deg. C. to 1350 deg. C., preferably from 1200 deg. C. to 1300 deg. C. 35. The process according to claim 14, wherein the silicon-containing and the trivalent cation-containing compounds are supplied in equimolar quantities with respect to the amount of silicon and the quantity of the trivalent cation. 36. The process according to claim 14, wherein the silicon-containing compound is supplied in a greater quantity than the trivalent cation compound with respect to the quantity of silicon and the quantity of the trivalent cation. 37. The process according to claim 14, wherein the silicon-containing compound is supplied in a lesser quantity than the trivalent cation compound with respect to the quantity of silicon and the quantity of the trivalent cation. 38. A method of stabilizing a silicon-substituted calcium phosphate material of claim 1, characterized by substituting a trivalent cation into the lattice. 39. The method according to claim 38, wherein the calcium phosphate material comprises hydroxyapatite or apatite. 40. The method according to claim 38, wherein the trivalent cation is yttrium. 41. The biomedical material according to claim 1, wherein the phase purity of the biomedical material, as measured by X-ray diffraction, is at least 97%. 42. The biomedical material according to claim 1, wherein the phase purity of the biomedical material, as measured by X-ray diffraction, is at least 99%. 43. The process according to claim 18, wherein yttrium is present in the material in an amount of up to 12 weight percent. 44. The process according to claim 24, wherein the silicate is present in the material in an amount of up to 12 weight percent. 45. The biomedical material of claim 1, wherein the silicate is present in the material in an amount of up to 12 weight percent. 46. The biomedical material according to claim 1, wherein the trivalent cation is yttrium. 47. The process of claim 24, wherein the silicate is present in the material in an amount of greater than 5.3 weight percent and up to 13 weight percent. 48. The process of claim 24, wherein the silicate is present in the material in an amount of greater than 5.3 weight percent and up to 12 weight percent. 49. The process of claim 24, wherein the silicate is present in the material in an amount of greater than 13 weight percent and up to 20 weight percent. 50. The biomedical material of claim 1, wherein the silicate is present in the material in an amount of greater than 5.3 weight percent and up to 13 weight percent. 51. The biomedical material of claim 1, wherein the silicate is present in the material in an amount of greater than 5.3 weight percent and up to 12 weight percent. 52. The biomedical material of claim 1, wherein the silicate is present in the material in an amount of greater than 13 weight percent and up to 20 weight percent.
法律状态
(US7695740) LEGAL DETAILS FOR US2007003634  Actual or expected expiration date=2026-01-30    Legal state=ALIVE    Status=GRANTED     Event publication date=2005-06-29  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US11168420  Application date=2005-06-29  Standardized application number=2005US-11168420     Event publication date=2005-06-29  Event code=US/EXMR  Event type=Administrative notifications  USPTO Examiner Name Primary Examiner: ARNOLD, ERNST V    Event publication date=2005-06-29  Event code=US/ART  Event type=Administrative notifications  USPTO Art Group  ART=1616     Event publication date=2005-06-29  Event code=US/ENT  Event type=Administrative notifications  Entity Status Set to Undiscounted Business Entity Status: UNDISCOUNTED    Event publication date=2005-06-29  Event code=US/AIA  Event type=Administrative notifications  First Inventor File Indicated:  AIA=No     Event publication date=2005-06-29  Event code=US/DK  Event type=Examination events  Attorney Docket Number Docket Nbr: GIBS3001/REF    Event publication date=2005-06-29  Event code=US/CUST  Event type=Examination events  Attorney/Agent Customer Number Customer Nbr: 23364    Event publication date=2005-08-05  Event code=US/INCD  Event type=Examination events  Event type=OAO  Notice Mailed--Application Incomplete--Filing Date Assigned    Event publication date=2006-01-18  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2006-03-21  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2007-01-04  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2007003634  Publication stage Code=A1  Publication date=2007-01-04  Standardized publication number=US20070003634     Event publication date=2007-01-04  Event code=US/PGPUBN  Event indicator=Pos  Event type=Examination events  Event type=OAO  PG-Pub Issue Notification    Event publication date=2007-08-28  Event code=US/CTNF  Event type=Examination events  Event type=OA  Event type=OAO  Non-Final Rejection    Event publication date=2008-02-29  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2008-02-29  Event code=US/CTNFR  Event type=Examination events  Event type=OAI  Response after Non-Final Action    Event publication date=2008-02-29  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2008-05-20  Event code=US/CTFR  Event type=Examination events  Event type=OA  Event type=OAO  Final Rejection    Event publication date=2008-12-05  Event code=US/RCEX  Event type=Examination events  Event type=RCE  Event type=OAI  Request for Continued Examination (RCE)    Event publication date=2008-12-05  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2009-01-05  Event code=US/DRCECAP  Event type=RCE  Event type=OAO  Disposal for a RCE / CPA / R129    Event publication date=2009-03-16  Event code=US/CTNF  Event type=Examination events  Event type=OA  Event type=OAO  Non-Final Rejection    Event publication date=2009-09-21  Event code=US/CTNFR  Event type=Examination events  Event type=OAI  Response after Non-Final Action    Event publication date=2009-09-21  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2009-10-05  Event code=US/EXIN  Event type=Examination events  Event type=OAO  Event type=INT  Examiner Interview Summary Record (PTOL - 413)    Event publication date=2009-11-19  Event code=US/EXAC  Event type=Examination events  Event type=OAO  Examiner's Amendment Communication    Event publication date=2009-11-20  Event code=US/NOAM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Mail Notice of Allowance    Event publication date=2009-11-20  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2010-01-26  Event code=US/M327  Event type=Examination events  Event type=OAO  Miscellaneous Communication to Applicant - No Action Count    Event publication date=2010-02-27  Event code=US/APRDY  Event indicator=Pos  Event type=Examination events  Application Is Considered Ready for Issue    Event publication date=2010-03-24  Event code=US/PAT  Event indicator=Pos  Event type=Event indicating In Force  Patented Case    Event publication date=2010-03-24  Event code=US/ISSM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Event type=Restitution or restoration  Issue Notification Mailed    Event publication date=2010-04-13  Event code=US/B2  Event indicator=Pos  Event type=Event indicating In Force  Granted patent as second publication  Publication country=US  Publication number=US7695740  Publication stage Code=B2  Publication date=2010-04-13  Standardized publication number=US7695740     Event publication date=2010-04-13  Event code=US/354  Event indicator=Pos  Event type=Extension of term of duration of protection  Patent term extended under  35 U.S.C 154(b) until/for Delays (A,B,C): 523  Overlap Delays: 0  Non Overlap Delays: 523   PTO Office Delays: 0  Applicant Delays: 308  Adjustment total:  Number of days of extension=215    Event publication date=2013-04-23  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=3     Event publication date=2013-10-15  Event code=US/FPAY  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Fee payment recorded   Annual fees payment date=2013-10-15     Year of payment of annual fees=4     Event publication date=2017-04-25  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=7     Event publication date=2017-10-13  Event code=US/M1552  Event type=Payment or non-payment notifications  Payment of Maintenance Fee, 8th Year, Large Entity
专利类型码
A1B2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部